Everolimus is an oral mTOR (mammalian target of rapamycin) inhibitor used in oncology and transplant medicine to suppress cell growth, proliferation, and angiogenesis. It is a derivative of sirolimus and was developed to improve bioavailability and pharmacokinetic properties. Everolimus was introduced in the early 2000s following extensive research into mTOR pathway inhibition. The drug received its first approvals for use in organ transplant rejection prevention and later for the treatment of various cancers, including renal cell carcinoma and breast cancer. Its ability to selectively target intracellular signaling pathways marked a major advancement in targeted therapy. Over time, everolimus has been approved for additional indications such as neuroendocrine tumors and tuberous sclerosis complex. Its development represents a significant milestone in precision medicine.
BRAND NAMES
Afinitor – Used mainly in cancer treatment and tuberous sclerosis–related conditions.
Zortress – Used to prevent organ transplant rejection.
Certican – Also used in transplant medicine, particularly in Europe and other regions.
